Our results thus may provide new evidence for LSCs-targeted therapy in APL patients based on the following facts: 1) PML-RARα can be detected in more than 95% of APL patients [2], 2) long-term follow-up of newly diagnosed patients with APL treated with single ATO therapy shows a high 5-year disease-free survival (DFS) rate and overall survival (OS) rate [35-37]. This evidence concerns the gene RARA and acute promyelocytic leukemia.